TORONTO--(BUSINESS WIRE)---- $OG #HealthyFoodForLess--Organic Garage reports its year-end financial results for fiscal 2020.
Business Wire Industry News
Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today reported updated clinical response and translational data from DeCidE1, its Phase 2 study evaluating the safety and efficacy of DPX-Survivac with intermittent low-dose cyclophosphamide (CPA) in patients with recurrent, advanced platinum-sensitive and -resistant ovarian can
AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A
ALAMEDA, Calif. & LONDON, Ontario--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today a research collaboration where Sernova will utilize AgeX’s UniverCyteTM gene technology to generate immune-protected universal therapeutic cells for use in combination with Sernova’
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Jefferies 2020 Virtual Healthcare Conference taking place June 2-4, 2020. The Company’s presentation will be on Thursday, June 4, 2020 at 2:30 p.m. ET. Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at http://ir.zymeworks.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of a Commercial Advisory Board consisting of leading experts in public health policy, epidemiology, and vaccine development. The Commercial Advisory Board will work closely with VBI’s management team on pre-commercialization and commercialization activities and strategy fo
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference. Presentation Details: Event: Jefferies Virtual Healthca
TROY, Mich.--(BUSINESS WIRE)--Tygrus LLC announced today that tests conducted by a Center for Disease Control and Prevention (CDC) authorized Bio Safety Level 3 laboratory on its new ingredient, Tydracide, showed that the formulation eliminated the SARS-CoV-2 virus in 1 minute at greater than 5-Log (99.999%) reduction. The tests were conducted on the SARS-CoV-2 virus, the actual virus that causes COVID-19 and not a surrogate virus. Additional preliminary testing has shown efficacy on other enve
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Chinook Therapeutics, Inc. (“Chinook”), a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier, President and Chief Executive Officer, will present an overview of the company and its pipeline at the Jefferies Virtual Healthcare Conference at 3:30 p.m. EDT on Wednesday, June 3, 2020. To access the live we
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc. announced today it has initiated a natural history study of Huntington’s disease (HD) called SHIELD HD.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has entered into a debt financing facility for up to $50 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. “This partnership with K2HV complements our recent $57.5 million equity raise, strengthening the financial position and flexibility of
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), today announced that on May 26, 2020 it received a Staff Delisting Determination letter (the “Determination”) from The Nasdaq Stock Market, LLC setting forth a determination to delist the Company's common shares from The Nasdaq Capital Market
Virna Therapeutics and University of Toronto Announce Licensing of Neutralizing Monoclonal Antibodies to Treat COVID-19
BOSTON & TORONTO--(BUSINESS WIRE)--Virna Therapeutics and University of Toronto Announce Licensing of Neutralizing Monoclonal Antibodies to Treat COVID-19
AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #antibodies--AbCellera closes US$105 million Series B financing to further advance world-leading antibody drug discovery platform.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare”), a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, today announced it has entered into an exclusive, worldwide research collaboration with Bristol Myers Squibb (BMS) (NYSE:BMY). “This collaboration will help to ensure that our novel discoveries are being broadly prosecuted in the searc
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced the completion of the rolling submission of a New Drug Application (“NDA”) to the United States Food and Drug Administration (“FDA”) for voclosporin as a potential treatment for lupus nephritis (“LN”), a serious inflammation of
Abacus Health Products Announces ISS and Glass Lewis Recommendations For its Proposed Acquisition by Charlotte’s Web; Change to Virtual Only Special Meeting of Shareholders
WOONSOCKET, R.I. & TORONTO--(BUSINESS WIRE)---- $ABAHF #AbacusHealthProducts--Abacus Health Products announces recommendations for its proposed acquisition by Charlotte’s Web; Change to virtual only Special Meeting